In conclusion, the combination of NY‐ESO‐1 and p53 antibody responses to CEA and CA19‐9 increased the diagnostic accuracy for gastric cancer; thus, NY‐ESO‐1 and p53 antibodies may be useful tumor markers for gastric cancer. This evidence concerns the gene CEACAM5 and gastric cancer.